Clinical trials: Glioma Tumor Recurrence
Recurrent Glioblastoma
FMISO PET Study of Glioblastoma
In this research study, the investigators are using FMISO-PET and MRI scans to explore the delivery of bevacizumab to the blood vessels in patient's with recurrent glioblastoma before and after treatment.
- Trial name
- NCT02076152
- Testing
- FMISO PET, MRI, Bevacizumab
- Where
- United States
- Volunteers
- 11 people
- Sponsor
- Massachusetts General Hospital
Brain and Central Nervous System Tumors
Brachytherapy in Treating Patients With Recurrent Malignant Glioma
RATIONALE: Brachytherapy uses radioactive material to kill cancer cells remaining after surgery. PURPOSE: Phase I trial to study the effectiveness of brachytherapy in treating patients who have recurrent malignant glioma.
- Trial name
- NCT00045474
- Testing
- adjuvant therapy, iodine I 125
- Where
- 9 sites in United States
- Sponsor
- National Cancer Institute (NCI)
Recurrent Glioblastoma
RNA-Lipid Particle (RNA-LP) Vaccines for Recurrent Adult Glioblastoma (GBM)
This is a Phase I study to demonstrate the manufacturing feasibility and safety, and to determine the maximum tolerated dose (MTD) of RNA-LP vaccines in adult patients with recurrent glioblastoma.
- Trial name
- ASPIRE (NCT06389591)
- Testing
- pp65 RNA loaded lipid particles, pp65 RNA-LPs (Drug Product 1 or DP1), RNA loaded lipid particles, RNA-LPs (Drug Product 2 or DP2)
- Where
- United States
- Volunteers
- 24 people
- Sponsor
- University of Florida
Glioma
The Utility of 18F-DOPA-PET in the Treatment of Recurrent High-grade Glioma
This proposal is for a pilot study comparing volumes of 18F-DOPA-PET avidity with contrast enhancement and T2 FLAIR on MRI. Investigators then plan to compare patterns of failure with target volumes, pre-treatment MRI changes and…
- Trial name
- NCT03242824
- Testing
- Fluorine F 18 Fluorodopa, Intensity-Modulated Radiation Therapy, Positron Emission Tomography
- Where
- United States
- Volunteers
- 21 people
- Sponsor
- Mayo Clinic
IDH1 Mutation, IDH2 Mutation
BGB-290 and Temozolomide in Treating Patients With Recurrent Gliomas With IDH1/2 Mutations
This phase I/II trial studies the side effects and how well BGB-290 and temozolomide work in treating patients with gliomas (brain tumors) with IDH1/2 mutations that have come back.
- Conditions
- IDH1 Mutation, IDH2 Mutation, Recurrent Glioblastoma, Recurrent WHO Grade II Glioma
- Trial name
- NCT03914742
- Testing
- PARP Inhibitor BGB-290, Temozolomide, Therapeutic Conventional Surgery
- Where
- 12 sites in United States
- Volunteers
- 67 people
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Astrocytoma, Grades II, III and IV, Glioblastoma Multiforme
Protein Phosphatase 2A Inhibitor, in Recurrent Glioblastoma
Background: The brain is separated from the rest of the blood stream by the blood-brain barrier. This is like a filter that protects the brain. But is also a challenge when medicines need to get into the brain.
- Conditions
- Astrocytoma, Grades II, III and IV, Glioblastoma Multiforme, Giant Cell Glioblastoma, Glioma
- Trial name
- NCT03027388
- Testing
- LB-100
- Where
- United States
- Volunteers
- 7 people
- Sponsor
- National Cancer Institute (NCI)
Recurrent or Progressive Diffuse Intrinsic Pontine Glioma
Re-Irradiation of Progressive or Recurrent DIPG
This is a single-arm, non-randomized study of re-irradiation of diffuse intrinsic pontine glioma (DIPG)
- Trial name
- NCT03126266
- Testing
- re-irradiation
- Where
- 18 sites in Australia, Canada and 1 more
- Volunteers
- 27 people
- Sponsor
- University of Calgary
Brain Tumor, Recurrent
Photodynamic Therapy (PDT) for Recurrent Pediatric Brain Tumors
The goal of this proposal is to evaluate a new Photodynamic Therapy (PDT) modification which could revolutionize the treatment of brain tumors in children and adults.
- Trial name
- NCT01682746
- Testing
- Photofrin (porfimer sodium) & photodynamic therapy.
- Where
- United States
- Volunteers
- 5 people
- Sponsor
- Harry T Whelan, MD
Glioblastoma
N-803 and PD-L1 t-haNK Combined With Bevacizumab for Recurrent or Progressive Glioblastoma
This study consists of 2 portions. The phase 2 portion is an open-label, single-arm study to evaluate the safety and efficacy of NAI, PD-L1 t-haNK, and bevacizumab combination therapy in participants with recurrent or progressive…
- Trial name
- NCT06061809
- Testing
- Bevacizumab, PD-L1 t-haNK, N-803
- Where
- 4 sites in United States
- Volunteers
- 34 people
- Sponsor
- ImmunityBio, Inc.
Glioma, Glioma, Malignant
Laparoscopically Harvested Omental Free Tissue Autograft to Bypass the Blood Brain Barrier (BBB) in Human Recurrent Glioblastoma Multiforme (rGBM)
This single center, single arm, open-label, phase I study will assess the safety of a laparoscopically harvested omental free flap into the resection cavity of recurrent glioblastoma multiforme (GBM) patients.
- Conditions
- Glioma, Glioma, Malignant, Glioblastoma, Glioblastoma Multiforme
- Trial name
- NCT04222309
- Testing
- Laparoscopically harvested omental free flap
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- Northwell Health
Medulloblastoma, Childhood, Rhabdomyosarcoma
A Study of LY2940680 in Pediatric Medulloblastoma or Rhabdomyosarcoma
The purpose of this study is to find a recommended dose level of LY2940680 that can be safely given to children with medulloblastoma or rhabdomyosarcoma that has returned or doesn't respond to initial treatment.
- Trial name
- NCT01697514
- Testing
- LY2940680
- Where
- 4 sites in United States
- Sponsor
- Eli Lilly and Company
Childhood Acute Promyelocytic Leukemia (M3), Childhood Atypical Teratoid/Rhabdoid Tumor
Vorinostat With or Without Isotretinoin in Treating Young Patients With Recurrent or Refractory Solid Tumors, Lymphoma, or Leukemia
This phase I trial is studying the side effects and best dose of vorinostat when given together with isotretinoin in treating young patients with recurrent or refractory solid tumors, lymphoma, or leukemia.
- Conditions
- Childhood Acute Promyelocytic Leukemia (M3), Childhood Atypical Teratoid/Rhabdoid Tumor, Childhood Burkitt Lymphoma, Childhood Chronic Myelogenous Leukemia
- Trial name
- NCT00217412
- Testing
- vorinostat, isotretinoin
- Where
- United States
- Volunteers
- 60 people
- Sponsor
- National Cancer Institute (NCI)
Breast Cancer, Non-Small Cell Lung Cancer
131-I-TM-601 Study in Adults With Solid Tumors
This study is designed to evaluate the ability of intravenously (IV)administered 131-I-labeled TM-601 (chlorotoxin) to provide tumor-specific localization(via radiographic imaging) in patients with recurrent or refractory primary…
- Conditions
- Breast Cancer, Non-Small Cell Lung Cancer, Melanoma, Colorectal Cancer
- Trial name
- NCT00379132
- Testing
- 131-I-TM-601 (chlorotoxin)
- Where
- 6 sites in United States
- Volunteers
- 60 people
- Sponsor
- TransMolecular
Brain and Central Nervous System Tumors, Childhood Germ Cell Tumor
Ixabepilone in Treating Young Patients With Solid Tumors or Leukemia That Haven't Responded to Therapy
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: This phase I trial is studying the side effects and best dose of ixabepilone in treating young…
- Conditions
- Brain and Central Nervous System Tumors, Childhood Germ Cell Tumor, Extragonadal Germ Cell Tumor, Kidney Cancer
- Trial name
- NCT00030108
- Testing
- ixabepilone
- Where
- 2 sites in United States
- Volunteers
- 30 people
- Sponsor
- National Institutes of Health Clinical Center (CC)
Glioblastoma Multiforme
Convection Enhanced Localized Administration of PRX321 With Real-time Imaging for Therapy of Recurrent Glioblastoma (CLARITY-1)
A Phase II, multi-center, open-label, single-arm study in up to 42 subjects with first recurrence or progression of GBM at up to 12 sites in Australia, Europe, Israel, and the United States.
- Trial name
- CLARITY-1 (NCT00797940)
- Testing
- IL-4PE
- Volunteers
- healthy volunteers welcome
- Sponsor
- Sophiris Bio Corp
Recurrent Glioblastoma
Randomized Study of Neo-adjuvant and Adjuvant Pembrolizumab With and Without Targeted Blood Brain Barrier Opening Using Exablate MRI-guided Focused Ultrasound (Exablate MRgFUS) for Recurrent Glioblastoma
To learn if the Exablate Model 4000 Type 2 ("Exablate System") with the DEFINITY® ultrasound contrast agent can temporarily disrupt the blood brain barrier in patients with recurrent (has grown back) glioblastoma who are…
- Trial name
- NCT05879120
- Testing
- Pembrolizumab, Exablate MRgFUS + neoadjuvant pembolizumab
- Where
- United States
- Sponsor
- M.D. Anderson Cancer Center
Adult Giant Cell Glioblastoma, Adult Glioblastoma
Dasatinib in Treating Patients With Recurrent Glioblastoma Multiforme or Gliosarcoma
This phase II trial studies how well dasatinib works in treating patients with glioblastoma multiforme or gliosarcoma that has come back.
- Conditions
- Adult Giant Cell Glioblastoma, Adult Glioblastoma, Adult Gliosarcoma, Recurrent Adult Brain Neoplasm
- Trial name
- NCT00423735
- Testing
- Dasatinib, Pharmacological Study
- Where
- 188 sites in United States, Canada and 1 more
- Volunteers
- 64 people
- Sponsor
- National Cancer Institute (NCI)
Medulloblastoma, Astrocytoma, Grade III
Phase I Study of Mebendazole Therapy for Recurrent/Progressive Pediatric Brain Tumors
This is a safety (Phase 1) trial using mebendazole for recurrent pediatric brain cancers that include medulloblastoma and high grade glioma, that are no longing responding to standard therapies.
- Conditions
- Medulloblastoma, Astrocytoma, Grade III, Glioblastoma, Anaplastic Astrocytoma
- Trial name
- NCT02644291
- Testing
- Mebendazole
- Where
- 2 sites in United States
- Volunteers
- 16 people
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Glioblastoma, Glioblastoma Multiforme
Treatment of Recurrent GBM With APG-157 Via Expanded Access
This expanded access request will evaluate APG-157, a botanical drug under development for other cancers, as potential treatment for recurrent Glioblastoma multiforme (GBM) patients.
- Trial name
- NCT05551013
- Testing
- APG-157
- Sponsor
- Aveta Biomics, Inc.
Glioblastoma
AB154 Combined With AB122 for Recurrent Glioblastoma
This is a phase 0/I exploratory study. Patients at first or second recurrence of glioblastoma will be enrolled. The study will be divided into two cohorts: Cohort A (safety cohort) and Cohort B (surgical patient cohort).
- Trial name
- NCT04656535
- Testing
- Zimberelimab, Domvanalimab
- Where
- 3 sites in United States
- Volunteers
- 46 people
- Sponsor
- Yale University